Xie Tingting, Qiu Qingchuan, Zhang Wei, Ning Tingting, Yang Wei, Zheng Congyi, Wang Chuan, Zhu Yingguo, Yang Daichang
Center of Engineering and Research of the Ministry of Education for Plant Biotechnology and Germplasm Utilization, Department of Genetics, College of Life Sciences, Wuhan University, Wuhan 430072, PR China.
Peptides. 2008 Nov;29(11):1862-70. doi: 10.1016/j.peptides.2008.07.014. Epub 2008 Jul 29.
Human insulin-like growth factor 1(hIGF-1) is essential for cell proliferation and used therapeutically in treating various diseases including diabetes mellitus. Here, we present that a recombinant hIGF-1(rhIGF-1) was expressed fused with the C-terminus of a rice luminal binding protein and accumulated highly in rice seeds, reaching 6.8+/-0.5% of total seed protein. The rhIGF-1 fusion was demonstrated to possess biological activity to stimulate cell proliferation. Importantly, the unprocessed transgenic seeds could significantly increase plasma rhIGF-1 level and reduce blood glucose of diabetic mice via oral delivery. Further studies suggested that transgenic seeds reduced blood glucose of diabetic mice by enhancing islet cells survival and increasing insulin secretion rather than increasing insulin sensitivity. These results indicated the potential of the novel fusion expression system in production and oral delivery of biologically active small peptides for diseases.
人胰岛素样生长因子1(hIGF-1)对细胞增殖至关重要,在治疗包括糖尿病在内的各种疾病中具有治疗用途。在此,我们展示了一种重组hIGF-1(rhIGF-1)与水稻腔结合蛋白的C末端融合表达,并在水稻种子中大量积累,达到种子总蛋白的6.8±0.5%。rhIGF-1融合蛋白被证明具有刺激细胞增殖的生物活性。重要的是,未经处理的转基因种子通过口服给药可显著提高糖尿病小鼠血浆rhIGF-1水平并降低血糖。进一步研究表明,转基因种子通过增强胰岛细胞存活和增加胰岛素分泌而非增加胰岛素敏感性来降低糖尿病小鼠的血糖。这些结果表明了这种新型融合表达系统在生产和口服递送具有生物活性的小肽用于疾病治疗方面的潜力。